Glenmark, Lay Line Genomics ink pact; Allergan pleads guilty in Botox case;

 @FiercePharma: Big Pharma behaving badly: A timeline of settlements. Article | Follow @FiercePharma

> Glenmark Pharmaceuticals said on Wednesday its unit has signed an in-licensing agreement with Italian biotechnology company Lay Line Genomics to commercialize antibody 'BXL1H5'. The molecule, which is a pain-killer monoclonal antibody for TrkA receptor responsible for chronic pain would be developed by Glenmark's biologics research and development center in Switzerland, the Indian company says in a statement. Story

> Allergan pleaded guilty and was ordered by a judge to pay $375 million to resolve allegations that the drug company marketed its Botox Therapeutic product for unapproved purposes, the U.S. Department of Justice said. Item

> Former shareholders of Quill Medical are suing Vancouver-based Angiotech Pharmaceuticals, alleging the drugmaker failed to meet contractual obligations and made misrepresentations when it was negotiating to buy Quill in 2006. Story

> FDA teams with pharma to find markers for adverse drug events. News

> DUSA Pharmaceuticals sought to terminate an agreement with a unit of GlaxoSmithKline to market and distribute its drug to treat scaly patches on the skin, in Latin America. Article

> Researchers tout accuracy of new prostate cancer biomarker. Article

> Jazz Pharmaceuticals has announced that the FDA website indicates that an Abbreviated New Drug Application (ANDA) for a generic version of Xyrem (sodium oxybate oral solution) 500 mg/ml was submitted on July 8.  Jazz Pharmaceuticals has not received a Paragraph IV certification with respect to this filing. Jazz release

> Fox launches $40M study to find Parkinson's biomarkers. News

> The U.K. National Institute for Health and Clinical Excellence said it can't recommend Johnson & Johnson's Simponi for treatment of psoriatic arthritis because evidence suggests it's not as effective as Pfizer's Enbrel. News

> Express Scripts has completed the spinoff of its Rx Outreach business unit as an independent nonprofit devoted to improving access to prescription medicines for low-income, uninsured Americans and working families. Article

> Banyan scores $26.3M DoD contract for TBI test. Story

> Delhi Network of Positive People (DNP+) is staging a mass demonstration in front of Udyog Bhavan on Wednesday to protest against the inclusion of intellectual property (IP) provisions in the EU-India free trade agreement (FTA) which they fear will affect people's access to affordable HIV/AIDS drugs. News

Biotech News

 @FierceBiotech: The 2010 Biotech Graveyard. Article | Follow @FierceBiotech

 @JohnCFierce: Sequencing upstart Pacific Biosciences outlines pricing of $230M IPO. Story |  Follow @JohnCFierce

> GSK spinout gets $35M bankroll for PhII pain program. Story

> Recession takes cruel bite out of the biotech industry. Item

> Kranda tapped as Vaccinogen CEO. News

Drug Delivery News

> Researchers give it to prostate cancer with both barrels. News

> Syracuse researcher takes on better delivery of arthritis meds. Article

> Cloaking device boldly delivers toxins to tumor. Report

> Access Pharmaceuticals rebrands, aims for siRNA. Story 

> Michelson Diagnostics markets microneedle imaging tool. Item

Medical Device News

> Argon acquires BD's critical care and catheter platforms. News

> Rosetta Genomics cuts 14 jobs. Item

> AdvaMed urges FDA to make minor 510(k) changes. Story

> Microbeads could replace traditional diabetes treatments. Article

> Synthes to divest Norian as part of settlement with gov't. News

> Wall Cardiovascular settles with Medtronic, Boston Sci. Story

And Finally... When mice are given drinking water laced with a special concoction of amino acids, they live longer than your average mouse, according to a new report in the October issue of Cell Metabolism, a Cell Press publication. The key ingredients in the supplemental mixture are so-called branched-chain amino acids, which account for 3 of the 20 amino acids (specifically leucine, isoleucine, and valine) that are the building blocks of proteins. Story

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.